| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0415d6923e2f80c6c8872becb568967 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 |
| filingDate |
2018-10-25^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e6621c11d36b002648f9321fcac0a94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb94bea246ba616d1d31b15ea11985ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53ed0c755c318c342b8ef5341ec8eb0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2df060e9e9c6319480bd1d298d7d4b7 |
| publicationDate |
2021-07-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021198359-A1 |
| titleOfInvention |
Anti-cd45-based lymphodepletion methods and uses thereof in conjction with act-based cancer therapies |
| abstract |
This invention provides a method for depleting a subject's immune cells, where the method includes administering to the subject an effective amount of a radiolabeled anti-CD45 antibody. This invention also provides a method for treating a subject afflicted with cancer, where the method includes (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's lymphocytes, and (ii) after a suitable time period, performing adoptive cell therapy on the subject to treat the subject's cancer. Finally, this invention provides an article of manufacture including (a) a radiolabeled anti-CD45 antibody, and (b) a label instructing the user to administer to a subject an amount of the antibody effective to deplete the subject's immune cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023137335-A3 |
| priorityDate |
2017-10-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |